^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FH-MagIC TCR-T

    i
    Other names: FH-MagIC TCR-T, MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells
    Associations

    News

    Trials
    Company:
    Fred Hutchinson Cancer Center, SignalOne Bio
    Drug class:
    MAGE-A1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    ATTAMAGE-A1: Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=1, Terminated, Fred Hutchinson Cancer Center | N=18 --> 1 | Trial completion date: Apr 2023 --> Aug 2022 | Suspended --> Terminated | Trial primary completion date: Apr 2023 --> Aug 2022; Terminated due to slow accrual.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA1 (MAGE Family Member A1)
    |
    EGFR mutation • HER-2 expression • HLA-A*02
    |
    Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • FH-MagIC TCR-T
    over2years
    ATTAMAGE-A1: Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=18, Suspended, Fred Hutchinson Cancer Center | Trial completion date: Dec 2024 --> Apr 2023 | Recruiting --> Suspended | Trial primary completion date: Dec 2024 --> Apr 2023
    Trial completion date • Trial suspension • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA1 (MAGE Family Member A1)
    |
    EGFR mutation • HER-2 expression • HLA-A*02
    |
    Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • FH-MagIC TCR-T